HK1105577A1 - Quinazoline derivatives useful as vanilloid antagonists - Google Patents
Quinazoline derivatives useful as vanilloid antagonistsInfo
- Publication number
- HK1105577A1 HK1105577A1 HK07107754A HK07107754A HK1105577A1 HK 1105577 A1 HK1105577 A1 HK 1105577A1 HK 07107754 A HK07107754 A HK 07107754A HK 07107754 A HK07107754 A HK 07107754A HK 1105577 A1 HK1105577 A1 HK 1105577A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- derivatives useful
- quinazoline derivatives
- vanilloid antagonists
- vanilloid
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Cereal-Derived Products (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0412769.2A GB0412769D0 (en) | 2004-06-08 | 2004-06-08 | Organic compounds |
PCT/EP2005/006253 WO2005120510A1 (en) | 2004-06-08 | 2005-06-08 | Quinazolinone derivatives useful as vanilloid antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1105577A1 true HK1105577A1 (en) | 2008-02-22 |
Family
ID=32696854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07107754A HK1105577A1 (en) | 2004-06-08 | 2007-07-18 | Quinazoline derivatives useful as vanilloid antagonists |
Country Status (30)
Country | Link |
---|---|
US (4) | US7960399B2 (it) |
EP (1) | EP1755606B2 (it) |
JP (2) | JP4703650B2 (it) |
KR (2) | KR101018607B1 (it) |
CN (1) | CN1956721B (it) |
AT (1) | ATE376833T1 (it) |
AU (2) | AU2005251476C1 (it) |
BR (1) | BRPI0511933B8 (it) |
CA (1) | CA2567821C (it) |
CY (1) | CY1107846T1 (it) |
DE (1) | DE602005003128T3 (it) |
DK (1) | DK1755606T4 (it) |
EC (2) | ECSP067067A (it) |
ES (1) | ES2293584T5 (it) |
GB (1) | GB0412769D0 (it) |
HK (1) | HK1105577A1 (it) |
HR (1) | HRP20070577T4 (it) |
IL (1) | IL179532A (it) |
MA (1) | MA28685B1 (it) |
MX (1) | MXPA06014249A (it) |
NO (1) | NO338181B1 (it) |
NZ (1) | NZ551630A (it) |
PL (1) | PL1755606T5 (it) |
PT (1) | PT1755606E (it) |
RU (2) | RU2449995C2 (it) |
SG (1) | SG153811A1 (it) |
SI (1) | SI1755606T2 (it) |
TN (1) | TNSN06405A1 (it) |
WO (1) | WO2005120510A1 (it) |
ZA (1) | ZA200609634B (it) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0412769D0 (en) * | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
GB0525068D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
CA2660957C (en) | 2006-08-23 | 2016-10-11 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
AU2007325940A1 (en) * | 2006-11-06 | 2008-06-05 | Neurogen Corporation | Cis-cyclohexyl substituted pyrimidinone derivatives |
WO2009010529A1 (en) | 2007-07-18 | 2009-01-22 | Novartis Ag | Synergistic combinations of vr-1 antagonists and cox-2 inhibitors |
US8915362B2 (en) | 2008-10-08 | 2014-12-23 | Ultimed, Inc. | Sharps container |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
EP2531510B1 (en) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
SG11201405810UA (en) | 2012-05-03 | 2014-11-27 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
WO2014138302A1 (en) * | 2013-03-05 | 2014-09-12 | University Of Notre Dame | Quinazolinone antibiotics |
US10016425B2 (en) | 2016-11-03 | 2018-07-10 | King Saud University | Anti-ulcerative colitis compound |
PE20211655A1 (es) | 2018-10-31 | 2021-08-24 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
JP2022520832A (ja) * | 2019-02-15 | 2022-04-01 | ノバルティス アーゲー | 眼表面疼痛を治療する方法 |
US20220162170A1 (en) | 2019-02-15 | 2022-05-26 | Novartis Ag | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤 |
US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
RU2755206C1 (ru) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия и лекарственный препарат на его основе |
JP2023536938A (ja) | 2020-08-06 | 2023-08-30 | ノバルティス アーゲー | 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの結晶形態及びその製剤 |
US20230416207A1 (en) * | 2020-11-17 | 2023-12-28 | Crystal Pharmatech Co., Ltd. | Crystalline forms of quinazolinone compound and process for preparing the same |
UY39681A (es) | 2021-03-26 | 2022-10-31 | Novartis Ag | Derivados de ciclobutilo 1,3–sustituidos y sus usos |
WO2024062389A1 (en) | 2022-09-21 | 2024-03-28 | Bausch + Lomb Ireland Limited | Crystalline polymorph forms of a trpv1 antagonist and formulations thereof |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US82365A (en) * | 1868-09-22 | thompson | ||
US95650A (en) * | 1869-10-12 | Improvement in machines for bending sheet-metal for cornices | ||
US49728A (en) * | 1865-09-05 | Improvement | ||
US220227A (en) * | 1879-10-07 | Improvement in stri klng-movements for clocks | ||
DE239090C (it) | 1906-11-01 | |||
US2749344A (en) | 1953-01-02 | 1956-06-05 | Burroughs Wellcome Co | Pyrimidine compounds |
DE1224316B (de) | 1961-03-18 | 1966-09-08 | Beiersdorf & Co Ag P | Verfahren zur Herstellung von 2-Methyl-3-(o-aethylphenyl)-4-oxo-3, 4-dihydrochinazolin und dessen Salzen |
DE1232152B (de) † | 1962-06-27 | 1967-01-12 | Heyden Chem Fab | Verfahren zur Herstellung von 3-Phenylchinazolinon-(4)-derivaten |
US3515787A (en) * | 1962-06-27 | 1970-06-02 | Squibb & Sons Inc | Compositions and methods for producing a muscle relaxing effect in an animal with 2,3 - substituted - 6 - amino-4-quinazolones |
GB1003802A (en) * | 1963-06-04 | 1965-09-08 | Searle & Co | Pyrimidinone derivatives |
DE1280874B (de) † | 1963-10-09 | 1968-10-24 | Boehringer Sohn Ingelheim | 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4) |
US3317388A (en) | 1964-11-20 | 1967-05-02 | Wallace & Tiernan Inc | Methods for treating pain |
US3864362A (en) | 1970-05-27 | 1975-02-04 | Chinoin Gyogyszer Es Vegyeszet | Iso flavones |
BE793594A (fr) | 1972-01-03 | 1973-07-02 | Pfizer | Nouvelles 6,7-dimethoxyquinazolines utiles comme analgesiques et tranquillisants |
GB1495305A (en) | 1975-09-12 | 1977-12-14 | Pfizer Ltd | 3-phenyl-4-oxo-4h-benzopyran derivatives |
US4501755A (en) | 1981-05-01 | 1985-02-26 | Pennwalt Corporation | Isoflavones useful as anti-inflammatory agents |
JPS59128376A (ja) * | 1983-01-13 | 1984-07-24 | Tanabe Seiyaku Co Ltd | キナゾリノン誘導体 |
SU1262927A1 (ru) | 1985-01-09 | 1997-11-20 | Институт физико-органической химии и углехимии АН УССР | Способ получения 6-бром-5-метилимидазо(4,5-в)пиридина |
JPS62201882A (ja) | 1985-11-18 | 1987-09-05 | Yamanouchi Pharmaceut Co Ltd | イソフラボン誘導体 |
JPS62193605A (ja) * | 1986-02-20 | 1987-08-25 | Toray Ind Inc | 半透性複合膜の製造方法 |
ZA873745B (en) | 1986-06-04 | 1988-10-26 | Daiichi Seiyaku Co | Benzopyran derivatives |
US5290780A (en) * | 1991-01-30 | 1994-03-01 | American Cyanamid Co. | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
WO1992013535A1 (en) * | 1991-02-06 | 1992-08-20 | Research Corporation Technologies, Inc. | Anticonvulsant substituted quinazolones |
US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
US5294617A (en) | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
US5284853A (en) | 1993-04-23 | 1994-02-08 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
EP0635263A3 (en) | 1993-06-28 | 1995-09-27 | American Cyanamid Co | Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue. |
HUT68558A (en) | 1993-07-20 | 1995-06-28 | Chinoin Gyogyszer Es Vegyeszet | Method for preparing isoflavon derivatives |
US5620978A (en) | 1994-01-03 | 1997-04-15 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor |
JPH07258224A (ja) | 1994-03-24 | 1995-10-09 | Dai Ichi Seiyaku Co Ltd | 二環性化合物 |
US5756502A (en) * | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
EP0815087B1 (en) * | 1995-03-14 | 2001-11-14 | Novartis AG | Trisubstituted phenyl derivatives |
US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
WO1997028118A1 (en) | 1996-02-05 | 1997-08-07 | Hoechst Celanese Corporation | Process for preparing anthranilic acids |
WO1997044041A1 (en) | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
FR2750862B1 (fr) | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
WO1998018781A2 (en) | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents |
IT1289154B1 (it) | 1997-01-03 | 1998-09-29 | Chiesi Farma Spa | Derivati di isoflavone loro preparazione e loro impiego terapeutico |
JPH10259176A (ja) * | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | 血管新生阻害作用を有する新規アミド誘導体及びその用途 |
US5948775A (en) | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
EP1009804B1 (en) | 1997-08-20 | 2003-10-29 | The Regents of the University of California | Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof |
EP1047711B1 (en) | 1998-01-22 | 2003-08-20 | The Regents of the University of California | Nucleic acid sequences encoding capsaicin receptors |
EA003876B1 (ru) | 1998-02-25 | 2003-10-30 | Дженетикс Инститьют, Ллс | Ингибиторы фосфолипазных ферментов |
US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
AU763824B2 (en) * | 1999-02-22 | 2003-07-31 | Medifron Dbt Co., Ltd. | Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof |
GB9920912D0 (en) | 1999-09-03 | 1999-11-10 | Indena Spa | Novel derivatives of flavones,xanthones and coumarins |
AU4742101A (en) | 2000-03-17 | 2001-10-03 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
MXPA03000458A (es) | 2000-07-20 | 2004-06-02 | Neurogen Corp | Ligandos receptores de capsaicina. |
AU8022901A (en) * | 2000-08-21 | 2002-03-04 | Pacific Corp | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
FR2815033B1 (fr) | 2000-10-06 | 2003-09-05 | Negma Lab | Derives de 7-carboxy-flavones, porcede pour leur preparation et leur application en therapeutique |
KR100883184B1 (ko) | 2000-12-11 | 2009-02-12 | 암젠 인코포레이션 | Cxcr3 길항제 |
US7915264B2 (en) | 2001-03-26 | 2011-03-29 | Novartis Ag | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain |
EP1414788A1 (en) * | 2001-07-31 | 2004-05-06 | Bayer HealthCare AG | Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists |
GB0128499D0 (en) | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
IL147416A (en) * | 2001-12-31 | 2008-11-26 | Israel State | Combined modalities for improved cancer treatment |
US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
US7381730B2 (en) | 2002-03-15 | 2008-06-03 | Bristol-Myers Squibb Company | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators |
WO2003106435A1 (en) * | 2002-06-18 | 2003-12-24 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
EP1560816A1 (en) | 2002-07-05 | 2005-08-10 | F. Hoffmann-La Roche Ag | Quinazoline derivatives |
EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
EP1558260A4 (en) | 2002-11-04 | 2006-10-25 | Nps Pharma Inc | CHINAZOLINONE COMPOUNDS AS CALCILYTIC |
JP4921162B2 (ja) | 2003-02-11 | 2012-04-25 | ヴァーナリス(ケンブリッジ)リミテッド | 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類 |
WO2004078719A1 (ja) | 2003-03-06 | 2004-09-16 | Ono Pharmaceutical Co., Ltd. | インドール誘導体化合物およびその化合物を有効成分とする薬剤 |
JP2006193426A (ja) | 2003-09-05 | 2006-07-27 | Sankyo Co Ltd | 置換された縮環ピリミジン−4(3h)−オン化合物 |
WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
WO2005049613A1 (en) | 2003-11-14 | 2005-06-02 | Merck Sharp & Dohme Limited | Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
CN1918128B (zh) | 2004-02-13 | 2011-01-26 | 万有制药株式会社 | 稠环4-氧代-嘧啶衍生物 |
GB0412768D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
US20090298856A1 (en) | 2005-05-11 | 2009-12-03 | Rebecca Elizabeth Brown | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) |
GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
WO2009010529A1 (en) | 2007-07-18 | 2009-01-22 | Novartis Ag | Synergistic combinations of vr-1 antagonists and cox-2 inhibitors |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
-
2004
- 2004-06-08 GB GBGB0412769.2A patent/GB0412769D0/en not_active Ceased
-
2005
- 2005-06-08 DK DK05750584.4T patent/DK1755606T4/da active
- 2005-06-08 JP JP2007526311A patent/JP4703650B2/ja active Active
- 2005-06-08 SI SI200530141T patent/SI1755606T2/sl unknown
- 2005-06-08 NZ NZ551630A patent/NZ551630A/en unknown
- 2005-06-08 US US11/569,802 patent/US7960399B2/en active Active
- 2005-06-08 CN CN200580016187.3A patent/CN1956721B/zh active Active
- 2005-06-08 SG SG200903909-0A patent/SG153811A1/en unknown
- 2005-06-08 BR BRPI0511933A patent/BRPI0511933B8/pt active IP Right Grant
- 2005-06-08 CA CA2567821A patent/CA2567821C/en active Active
- 2005-06-08 ES ES05750584T patent/ES2293584T5/es active Active
- 2005-06-08 EP EP05750584A patent/EP1755606B2/en active Active
- 2005-06-08 PT PT05750584T patent/PT1755606E/pt unknown
- 2005-06-08 WO PCT/EP2005/006253 patent/WO2005120510A1/en active IP Right Grant
- 2005-06-08 AT AT05750584T patent/ATE376833T1/de active
- 2005-06-08 RU RU2010112450/04A patent/RU2449995C2/ru active
- 2005-06-08 KR KR1020067025788A patent/KR101018607B1/ko active IP Right Grant
- 2005-06-08 PL PL05750584T patent/PL1755606T5/pl unknown
- 2005-06-08 RU RU2006146632/04A patent/RU2396261C2/ru active
- 2005-06-08 KR KR1020107019024A patent/KR20100101017A/ko not_active Application Discontinuation
- 2005-06-08 AU AU2005251476A patent/AU2005251476C1/en active Active
- 2005-06-08 DE DE602005003128T patent/DE602005003128T3/de active Active
- 2005-06-08 MX MXPA06014249A patent/MXPA06014249A/es active IP Right Grant
-
2006
- 2006-11-20 ZA ZA200609634A patent/ZA200609634B/xx unknown
- 2006-11-23 IL IL179532A patent/IL179532A/en active IP Right Grant
- 2006-12-07 EC EC2006007067A patent/ECSP067067A/es unknown
- 2006-12-07 TN TNP2006000405A patent/TNSN06405A1/en unknown
- 2006-12-28 MA MA29565A patent/MA28685B1/fr unknown
-
2007
- 2007-01-08 NO NO20070122A patent/NO338181B1/no unknown
- 2007-07-18 HK HK07107754A patent/HK1105577A1/xx active IP Right Maintenance
- 2007-12-20 HR HR20070577T patent/HRP20070577T4/hr unknown
-
2008
- 2008-01-03 CY CY20081100014T patent/CY1107846T1/el unknown
-
2009
- 2009-11-06 AU AU2009233684A patent/AU2009233684A1/en not_active Abandoned
-
2011
- 2011-01-21 JP JP2011010997A patent/JP5400812B2/ja active Active
- 2011-04-19 US US13/089,943 patent/US8211902B2/en active Active
-
2012
- 2012-02-14 EC ECSP12007067 patent/ECSP12007067A/es unknown
- 2012-03-29 US US13/434,248 patent/US8809528B2/en active Active
-
2014
- 2014-07-02 US US14/322,165 patent/US9102653B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL179532A0 (en) | Quinazoline derivatives useful as vanilloid antagonists | |
SG154435A1 (en) | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors | |
WO2006017054A3 (en) | Tricyclic-heteroaryl compounds useful as kinase inhibitors | |
SG154432A1 (en) | Quinazolinedione derivatives as parp inhibitors | |
MXPA06012595A (es) | Analogos de amino-tetrazoles y metodos de uso. | |
TW200617009A (en) | Organic compounds | |
TNSN07272A1 (en) | Substituted bis aryl and heteroaryl compounds as selective 5ht 2a antagonists | |
WO2006010591A3 (en) | Quinazoline derivatives | |
WO2007047646A3 (en) | Substituted dihydro-isoindolones useful in treating kinase disorders | |
AU2006243987A8 (en) | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof | |
MY146623A (en) | Substituted prolinamides, manufacturing, and the use thereof as medicaments | |
EP2305652A3 (en) | Trisubstituted quinazolinone derivatives as vanilloid antagonists | |
WO2006047415A3 (en) | FACTOR Xa COMPOUNDS | |
MXPA05013905A (es) | Compuestos de quinazolinona sustituidos por arilamina. | |
TW200628153A (en) | Novel compounds | |
MX2007001952A (es) | Compuestos y composiciones utiles como inhibidores de catepsina-s. | |
TNSN06410A1 (en) | Pyrrolopyridine derivatives and their use as crth2 antagonists | |
TW200745053A (en) | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | |
MX2007007554A (es) | Oxiarenos sustituidos. | |
WO2005123694A3 (en) | Quinazolinone compounds for the treatment of cough |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AM43 | Amendment of standard patent following opposition or revocation proceedings in the designated patent office (acc. sect 43 patent ordinance) |